These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18389916)

  • 1. Authorized sources of narcotic raw materials. Final rule.
    Fed Regist; 2008 Feb; 73(25):6843-51. PubMed ID: 18389916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(177):55343-7. PubMed ID: 15366181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of thresholds for the List I chemicals pseudoephedrine and phenylpropanolamine. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2010 Jul; 75(129):38915-22. PubMed ID: 20608288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Feb; 75(20):4973-82. PubMed ID: 20352663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information on foreign chain of distribution for ephedrine, pseudoephedrine, and phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Mar; 75(43):10168-72. PubMed ID: 20383917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled substances and List I chemical registration and reregistration fees. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2012 Mar; 77(51):15234-50. PubMed ID: 22420065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Import and production quotas for certain List I chemicals. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Jul; 72(131):37439-53. PubMed ID: 17674492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing the accumulation of surplus controlled substances at long term care facilities. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 May; 70(92):25462-6. PubMed ID: 15892213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification of registration requirements for individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2006 Dec; 71(231):69478-80. PubMed ID: 17171847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the regulation of iodine crystals and chemical mixtures containing over 2.2 percent iodine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Jul; 72(126):35920-31. PubMed ID: 17910137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule of controlled substances; placement of fospropofol into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2009 Oct; 74(192):51234-6. PubMed ID: 19877370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.